Use of immunomodulary agents is difficult in treating autoimmune hepatitis patients

Journal of Clinical Gastroenterology

Volumn 38, Issue 9, 2004, Pages 729-730

  Gordon, Fredric D ^a   Simpson, MaryAnn ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

AUTOIMMUNE HEPATITIS; CHRONIC LIVER DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG COST; EDITORIAL; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; SIDE EFFECT; STEROID THERAPY;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; TREATMENT OUTCOME;

EID: 4644278720     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000139177.33502.47     Document Type: Editorial

References (11)

1. Rakela J, Czaja AJ. Clinical, biochemical, and histologic features of HbsAg-negative chronic active hepatitis. In: Czaja AJ, Dickson ER, eds. Chronic Active Hepatitis: The Mayo Clinic Experience. New York: Marcel Dekker; 1986:69-82.
2. Aqel BA, Machicao V, Hamois DM, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastro. 2004.
3. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
4. Milkiewicz P, Ahmed M, Hathaway M, et al. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver. 1999;19:50-54.
5. Heneghan MA, McFarlane IG. Current and novel immunosuppression therapy for autoimmune hepatitis. J Hepatol. 2002;35:7-13.
6. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002;6:825-850.
7. Conti F, Frappier J, Dharancy S, et al. Interleukin-15 production during liver allograft rejection in humans. Transplantation. 2003;76:210-216.
8. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: A long-term pathologic study. Hepatology. 2002;32:185-192.
9. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7:302-310.
10. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002;8:519-526.
11. Gotz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc. 1999;31:430-431.